A five-year study in patients with juvenile idiopathic arthritis-associated uveitis found drug-induced disease remission did not persist once adalimumab was stopped after long-term treatment.
Search results for: hospital
Lupus Pregnancy Outcomes Improved Over the Past 2 Decades
NEW YORK (Reuters Health)—Pregnancy outcomes in women with systemic lupus erythematosus (SLE) have improved markedly over the past two decades, although pregnancy risks remain higher than in women without lupus, according to a trends analysis. “Thirty years ago, most women with SLE were advised to avoid pregnancy because of high risks for maternal and fetal…
Opioids Commonly Prescribed for Gout Attacks
NEW YORK (Reuters Health)—Nearly three in 10 patients seeking care at the emergency department (ED) for acute gout will be discharged with a prescription for opioids, new research shows. “Our study suggests a high use of prescription opioid in patients discharged from the ED with a diagnosis of gout, a condition that can be managed…
Ankylosing Spondylitis Patients Report Improved Quality of Life with Bimekizumab
Recent research shows bimekizumab may improve patient-reported outcomes and quality of life for ankylosing spondylitis (AS) patients…
Diet & Exercise: What’s the Economic Benefit for Overweight & Obese Patients with Knee OA?
New research recently found that, when combined with standard treatment, diet and exercise regimens are cost effective for overweight and obese patients with knee OA…
Ixekizumab vs. Adalimumab for PsA: How Do They Compare?
In a study of bDMARD-naive patients with active PsA and skin disease, ixekizumab proved more efficacious than adalimumab…
Results for Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
A study of nintedanib in patients with ILD associated with systemic sclerosis showed the treatment had only limited improvement. Although these patients had a lower rate of decline in forced vital capacity than those on placebo, nintedanib did not result in clinical benefits for other manifestations of systemic sclerosis…
Tanezumab’s Phase 3 Results for OA
In a recent study, tanezumab proved safe and effective in the treatment of knee and hip osteoarthritis…
ACR Pushes for Increased DXA Reimbursement
Broken hips are among the most serious injuries incurred by older adults, and many fractures are preventable. According to the Centers for Disease Control and Prevention (CDC), approximately 300,000 people over the age of 65 are hospitalized each year for hip fractures, with women (who have lower bone density than men) experiencing three-quarters of all…
Scientist Development Award Winner Probes Ethnic Disparities in Lupus
Recipient of a Rheumatology Research Foundation Scientist Development Award, Ashira Blazer, MD, focuses her research on racial and ethnic disparities in lupus. She looks beyond socioeconomic differences, differences in lifestyles and access to care to better understand the biologically determined differences behind disparate outcomes. With funding from the Foundation, she was able to investigate the…
- « Previous Page
- 1
- …
- 123
- 124
- 125
- 126
- 127
- …
- 326
- Next Page »